SCHEMBL2680105

SCHEMBL2680105

CC1(C)OB(c2cnn(CC(=O)O)c2)OC1(C)C

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.61
LIPG Q9Y5X9 3/20 0.38
PDK2 Q15119 4/20 0.37
DGAT1 O75907 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
LPL P06858 2/20 0.36
P4HB P07237 1/20 0.35
F2 P00734 2/20 0.35
F11 P03951 2/20 0.35
PRSS1 P07477 2/20 0.35
PRSS2 P07478 2/20 0.35
PRSS3 P35030 2/20 0.35
HIF1A Q16665 1/20 0.34
UCHL1 P09936 1/20 0.33
KLKB1 P03952 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PDGFRB P09619 1/20 0.33
KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12912195 0.88 FFAR1 (0.61) FFAR1LIPGDGAT1GSK3AGSK3B
SCHEMBL2544457 0.87 FFAR1 (0.59) FFAR1LIPGPDK2DGAT1GSK3A
SCHEMBL14232005 0.85 FFAR1 (0.58) FFAR1LIPGPDK2DGAT1GSK3A
SCHEMBL12049576 0.85 FFAR1 (0.58) FFAR1LIPGDGAT1GSK3AGSK3B
SCHEMBL17983793 0.84 FFAR1 (0.57) FFAR1LIPGDGAT1GSK3AGSK3B
SCHEMBL4099087 0.84 FFAR1 (0.57) FFAR1LIPGDGAT1GSK3AGSK3B
SCHEMBL253500 0.84 FFAR1 (0.57) FFAR1PDK2DGAT1GSK3AGSK3B
SCHEMBL938503 0.82 FFAR1 (0.54) FFAR1DGAT1GSK3AGSK3BUCHL1
SCHEMBL30291228 0.82 FFAR1 (0.54) FFAR1
SCHEMBL29236822 0.82 FFAR1 (0.54) FFAR1LIPGPDK2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747250-A1 KINASE INHIBITORS The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) 2026-05-27 EP disclosed
EP-4719592-A1 BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION Centennial Therapeutics, LLC (US) 2026-04-08 EP disclosed
EP-4713095-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS Chengdu Anticancer Bioscience, Ltd. (CN) 2026-03-25 EP disclosed
EP-4695239-A1 DISUBSTITUTED PYRIMIDINE COMPOUNDS FOR KETOHEXOKINASE INHIBITION Centennial Therapeutics, LLC (US) 2026-02-18 EP disclosed
WO-2025054339-A1 TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT ARCUS BIOSCIENCES, INC. (US) 2025-03-13 WO disclosed
WO-2025019585-A1 KINASE INHIBITORS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-01-23 WO disclosed
US-20240409530-A1 Disubstituted Pyrimidine Compounds for Ketohexokinase Inhibition CENTENNIAL THERAPEUTICS, LLC 2024-12-12 US disclosed
WO-2024249612-A1 BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION CENTENNIAL THERAPEUTICS, LLC (US) 2024-12-05 WO disclosed
WO-2024240088-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE , LTD. (CN) 2024-11-28 WO disclosed
WO-2024216034-A1 DISUBSTITUTED PYRIMIDINE COMPOUNDS FOR KETOHEXOKINASE INHIBITION CENTENNIAL THERAPEUTICS, LLC (US) 2024-10-17 WO disclosed
US-20100173901-A1 Substituted Heterocyclic Compounds INCYTE CORPORATION (US) 2010-07-08 US disclosed
WO-2010075270-A1 4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS INCYTE CORPORATION (US) 2010-07-01 WO disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100130467-A1 TRIAZOLOTRIAZINES AS KINASE INHIBITORS INCYTE CORPORATION 2010-05-27 US disclosed
US-7683060-B2 Triazolotriazines as kinase inhibitors INCYTE CORPORATION (US) 2010-03-23 US disclosed
WO-2010000364-A1 PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES MERCK PATENT GMBH (DE) 2010-01-07 WO disclosed
EP-2099447-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS Incyte Corporation (US) 2009-09-16 EP disclosed
WO-2009097233-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2009-08-06 WO disclosed
WO-2008064157-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS INCYTE CORPORATION (US) 2008-05-29 WO disclosed
US-20080039457-A1 TRIAZOLOTRIAZINES AS KINASE INHIBITORS INCYTE CORPORATION (US) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD FFAR1 3621/4885LIPG 2790/4885PDK2 689/4885
US-20100173901-A1 Substituted Heterocyclic Compounds HRH4, HRH2, HRH1 FFAR1 285/4885LIPG 4658/4885PDK2 3635/4885
US-20080039457-A1 TRIAZOLOTRIAZINES AS KINASE INHIBITORS MET, ERBB2, RET FFAR1 3285/4885LIPG 3488/4885PDK2 1334/4885
US-20240409530-A1 Disubstituted Pyrimidine Compounds for Ketohexokinase Inhibition KHK, GCK, HK1 FFAR1 2849/4885LIPG 1304/4885PDK2 9/4885
US-20100130467-A1 TRIAZOLOTRIAZINES AS KINASE INHIBITORS MET, ERBB2, RET FFAR1 3285/4885LIPG 3488/4885PDK2 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.